We present the preliminary findings on the ability of our novel whole-body MRI using Dual-Echo T2-weighted acquisition for Enhanced Conspicuity of Tumors (WBMRI-DETECT) for detection and longitudinal assessment of therapy response in multiple myeloma (MM). Data from 4 MM patients undergoing induction therapy at 4 timepoints in an ongoing prospective research study are presented. Our results show that WBMRI-DETECT provides higher SNR, improved lesion conspicuity with shorter scan times compared to WBMRI-STIR and WBMRI-DWIBS, and minimal geometric distortions compared to WBMRI-DWIBS. In addition, quantitative FF measurements from WBMRI can serve as a prognostic imaging biomarker for the treatment response assessment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords